<DOC>
	<DOCNO>NCT00645177</DOCNO>
	<brief_summary>The purpose study determine effect ABT-869 plus paclitaxel compare paclitaxel alone disease progression metastatic breast cancer .</brief_summary>
	<brief_title>Phase 2 Study ABT-869 Combination With Paclitaxel Versus Paclitaxel Alone Treat Metastatic Breast Cancer</brief_title>
	<detailed_description>Only open-label lead-in portion study enrol ( n=10 ) . The randomized portion initiate . N = approximately 102 ( 90 randomize 1:1 ratio Phase 2 , approximately 6-12 enrolled open-label lead-in ass tolerability combination ) Phase 2 , randomize , placebo-controlled , double-blind , multi-center study efficacy tolerability ABT-869 + paclitaxel versus placebo ABT-869 + paclitaxel subject document metastatic breast cancer first line metastatic therapy setting . An initial open-label , lead-in cohort six subject monitor 2 cycle ( 8 week ) assess PK interaction safety combination 0.20 mg/kg QD ABT-869 paclitaxel ( 90 mg/m2 ) . Enrollment randomized portion begin cohort complete two cycle ( 8 week ) therapy toxicity prohibit cohort continue Cycle 3 . Alternative dos may explore base tolerability combination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subject must female &gt; 18 year age . Subject must diagnose adenocarcinoma breast . Subject must metastatic disease locally recurrent disease amenable surgical resection curative intent . No prior chemotherapy locally recurrent metastatic breast cancer . At least 12 month since prior adjuvant neoadjuvant chemotherapy ( include prior taxane therapy prior antiangiogenic therapy [ i.e . bevacizumab TKI ] ) . No HER2 overexpression ( 3+ ) breast cancer ( unless treat trastuzumab lapatinib ) . Subject measurable disease RECIST criterion ( randomize portion ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 . Subject must adequate bone marrow , renal hepatic function . Subject must PTT &lt; 1.5 x ULN INR &lt; 1.5 . Subject receive anticancer therapy ( chemotherapy ) include investigational agent , biologic therapy within 21 day within period define 5 half life , whichever short , prior Study Day 1 . Subject recover less equal grade 1 clinically significant adverse effects/toxicities previous therapy . Subject receive radiation therapy within 14 day Study Day 1 . Subject receive anticancer hormonal therapy within 14 day Study Day 1 . Subject undergone major surgery within 21 day Study Day 1 . The subject untreated brain meningeal metastasis . Subject receive therapeutic anticoagulation therapy . Subject history currently exhibit clinically significant cancer relate event bleed ( e.g. , hemoptysis ) . Subject currently exhibit symptomatic persistent , uncontrolled hypertension . Subject history myocardial infarction , stroke , transient ischemic attack ( TIA ) within 6 month study day 1 . Subject document left ventricular ( LV ) ejection fraction &lt; 50 % Subject know autoimmune disease renal involvement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>